IRCT20200324046847N1 IRCT 2020-03-31 Tehran University of Medical Sciences Treatment of patients with Corona virus infection Study the Efficacy and Safety of SeptimebTM in the Treatment of COVID-19 Infection in Iranian Patients: A Clinical Trial (Case Series) 2020-03-28 anticipated 30 Complete https://irct.ir/trial/46720 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Infection caused by COVID-19. Intervention group: Patients who suffer from sever (ARDS patients who are not admitted in ICU) or very severe (ARDS or related symptoms and signs who are admitted in ICU) complications of COVID-19, received 150 mg of SeptimebTM in 500 ml of DW 5%, infused over 1.5 hours on the first day. All hemodynamic data are monitored during the infusion and in case of any negative hemodynamic deterioration, dermal rash, urticaria or anaphylactic reaction, the infusion discontinued. In absence of the mentioned complications the treatment is continued by administration of 300 mg of the drug that will be infused in 500 ml of DW5%, every day for up to 14 days (the duration of treatment will be adjusted based on the severity of symptom and sign of the patients).. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information.